Dynamic Technology Lab Private Ltd Invests $1.35 Million in IQVIA Holdings Inc. $IQV

Key Points

• Dynamic Technology Lab Private Ltd has invested approximately $1.35 million in IQVIA Holdings Inc., acquiring 7,660 shares in the first quarter.
• Insider trading includes significant sales, with Eric Sherbet selling 5,800 shares for over $1.1 million, reflecting a 17.59% decrease in position.
• IQVIA reported a quarterly earnings beat with $2.81 per share and revenue of $4.02 billion, surpassing analyst expectations.

Dynamic Technology Lab Private Ltd purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 7,660 shares of the medical research company's stock, valued at approximately $1,351,000.

A number of other institutional investors also recently modified their holdings of the business. UniSuper Management Pty Ltd raised its holdings in shares of IQVIA by 3.1% during the 1st quarter. UniSuper Management Pty Ltd now owns 16,654 shares of the medical research company's stock worth $2,936,000 after buying an additional 500 shares in the last quarter. Punch & Associates Investment Management Inc. raised its holdings in shares of IQVIA by 16.6% during the 1st quarter. Punch & Associates Investment Management Inc. now owns 68,765 shares of the medical research company's stock worth $12,123,000 after buying an additional 9,791 shares in the last quarter. Petrus Trust Company LTA raised its holdings in shares of IQVIA by 151.1% during the 1st quarter. Petrus Trust Company LTA now owns 3,071 shares of the medical research company's stock worth $541,000 after buying an additional 1,848 shares in the last quarter. Nissay Asset Management Corp Japan ADV raised its holdings in shares of IQVIA by 0.8% during the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 22,428 shares of the medical research company's stock worth $3,954,000 after buying an additional 181 shares in the last quarter. Finally, NewEdge Advisors LLC raised its holdings in shares of IQVIA by 13.9% during the 1st quarter. NewEdge Advisors LLC now owns 21,576 shares of the medical research company's stock worth $3,804,000 after buying an additional 2,626 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Insider Activity

In related news, insider Eric Sherbet sold 5,800 shares of the company's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider owned 27,178 shares in the company, valued at $5,165,178.90. This represents a 17.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the sale, the insider owned 2,910 shares in the company, valued at approximately $557,352.30. The trade was a 15.87% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company's stock.

IQVIA Trading Up 2.0%

Shares of IQV stock opened at $187.75 on Monday. The stock has a market cap of $31.92 billion, a price-to-earnings ratio of 27.17, a PEG ratio of 2.06 and a beta of 1.32. The stock has a 50-day moving average of $179.88 and a 200-day moving average of $167.23. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $249.43.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.04. The company had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business's quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Evercore ISI boosted their price target on IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a report on Wednesday, July 9th. William Blair reaffirmed an "outperform" rating on shares of IQVIA in a report on Wednesday, July 23rd. Cowen reaffirmed a "buy" rating on shares of IQVIA in a report on Wednesday, July 23rd. JPMorgan Chase & Co. lowered their target price on IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a report on Monday, May 19th. Finally, Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a report on Thursday, May 22nd. Seventeen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $229.86.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.